GammaDelta Therapeutics was founded on new research into gamma delta (γδ) T cells, led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute, funded in part by the charity Cancer Research UK.

Gamma delta T cells are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting this work to develop improved immunotherapies for cancer and other serious immune related diseases.